Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关实验视频

Updated: Jun 28, 2025

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates
06:10

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Published on: May 9, 2025

195

在活体中直接进行CAR T细胞工程.

Lauralie Short1, Robert A Holt2, Pieter R Cullis3

  • 1Michael Smith Genome Sciences Department, BC Cancer Research Institute, Vancouver, BC, Canada; Interdisciplinary Oncology Program, University of British Columbia, Vancouver, BC, Canada.

Trends in pharmacological sciences
|April 13, 2024
PubMed
概括

相关概念视频

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

GPNMB-directed CAR T cell therapy against MiT/TFE-family fusion-driven solid tumors.

Nature cancer·2026
Same author

Liposomal lipid nanoparticles containing dihydrosphingomyelin exhibit improved stability and extended hepatic and extrahepatic transfection.

Journal of controlled release : official journal of the Controlled Release Society·2026
Same author

Engagement of the TCR against an oncolytic virus generates a population of effector CAR T cells with potent antitumor activity.

Science advances·2026
Same author

Direct Counting of mRNA Copies Inside Individual Lipid Nanoparticles Using In Situ Lysis and Labeling.

Analytical chemistry·2026
Same author

Ionizing radiation enhances CAR T-cell infiltration and efficacy in solid tumors.

Frontiers in immunology·2026
Same author

Hybrid Lipid Nanoparticles Containing Iron Oxide Nanoparticles and Doxorubicin.

Langmuir : the ACS journal of surfaces and colloids·2026

化学抗原受体 (CAR) T细胞疗法对血液癌症具有前景. 在体内生成CAR-T细胞提供了一个潜在的更简单和更具成本效益的替代品,而不是体外制造,正在进行的研究解决临床挑战.

科学领域:

  • 免疫治疗是一种免疫疗法.
  • 细胞疗法细胞疗法
  • 在瘤学瘤学.

背景情况:

  • 化学抗原受体 (CAR) T细胞疗法是复发性/耐药性血液癌症的有效治疗方法.
  • 目前的ex vivo制造复杂且昂贵,限制了广泛采用.
  • 在体内生成CAR-T细胞是一种新兴的替代策略.

研究的目的:

  • 审查ex vivoCAR T细胞制造过程.
  • 在体内探索CAR T细胞生成策略.
  • 讨论体内CAR T细胞治疗的潜力和挑战.

主要方法:

  • 对ex vivo制造工艺的审查.
  • 对体内CAR T细胞生成的临床前数据的分析.
  • 交付方法的讨论,包括纳米粒子配方的核酸和病毒载体.

主要成果:

  • 活体内策略旨在简化CAR T细胞的生产,降低复杂性和成本.
  • 临床前模型证明了体内生成的CAR T细胞的效力.
  • 潜在的应用范围超出了CAR T细胞治疗目前的适用范围.

结论:

关键词:
它们是DNA DNA DNA DNA.仿制性抗原受体的复制性受体.人工合成的lentiviruses病毒在体内进行细胞治疗.脂质纳米颗粒的使用方法它们是mRNARNA.聚合物纳米粒子的聚合物纳米粒子.

更多相关视频

Generation of Human Chimeric Antigen Receptor Regulatory T Cells
10:29

Generation of Human Chimeric Antigen Receptor Regulatory T Cells

Published on: January 3, 2025

1.3K
Author Spotlight: Enhancing CAR-T Cell Function in Syngeneic Tumor Models
06:22

Author Spotlight: Enhancing CAR-T Cell Function in Syngeneic Tumor Models

Published on: February 2, 2024

3.5K

相关实验视频

Last Updated: Jun 28, 2025

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates
06:10

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Published on: May 9, 2025

195
Generation of Human Chimeric Antigen Receptor Regulatory T Cells
10:29

Generation of Human Chimeric Antigen Receptor Regulatory T Cells

Published on: January 3, 2025

1.3K
Author Spotlight: Enhancing CAR-T Cell Function in Syngeneic Tumor Models
06:22

Author Spotlight: Enhancing CAR-T Cell Function in Syngeneic Tumor Models

Published on: February 2, 2024

3.5K
  • 在体内产生CAR T细胞是一种有希望的,可能更容易获得的治疗方法.
  • 需要进一步的研究,以应对临床准备的传递特异性,长期疗效和安全性方面的挑战.
  • 这种方法可以扩大CAR T细胞治疗在各种疾病中的影响.